Oncology
Squamous Cell Cancer of the Head and Neck
0
Pipeline Programs↗
3
Active Trials↗
3
Companies Involved↗
Squamous Cell Cancer of the Head and Neck is an early-stage landscape with 0 programs across 3 companies. The most active players are Merck & Co., GSK, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
17
clinical trials
Completed10 · 59%
Active, not recruiting3 · 18%
Unknown status2 · 12%
Terminated1 · 6%
Withdrawn1 · 6%
Clinical Trials
Trial Activity
17 trials
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Active, not recruiting·—·Phase 2·NCT02769520·27 enrolled
Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck
Completed·—·Phase 2·NCT02058849·13 enrolled
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Completed·—·Phase 2·NCT03057613·18 enrolled
Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck
Completed·—·Phase 1·NCT00003200·22 enrolled
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Completed·—·Phase 2·NCT01044433·44 enrolled
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Terminated·—·Phase 2·NCT01192815·2 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)